Shareholders in 2seventy bio, Inc. ( NASDAQ:TSVT ) had a terrible week, as shares crashed 22% to US$3.92 in the ...

Cash Runway: Expected to extend beyond 2027. 2seventy bio Inc (NASDAQ:TSVT) successfully completed the sale of its oncology and autoimmune R&D pipeline to Regeneron, streamlining operations. The ...

TD Cowen analyst Yaron Werber maintained a Hold rating on 2seventy bio (TSVT – Research Report) today. The company’s shares closed ...

Inc. (TSVT) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $1 per share a year ago. These figures are adjusted for ...

Total revenue for Q3 was $13.5 million, missing the $16.2 million analyst estimate. Operating expenses dropped by 24%, ...

The latest announcement is out from 2seventy bio ( (TSVT) ). 2seventy bio reported impressive third-quarter results with a 42% increase in ...